Rationale: Loss of Tbx1 and decrease of retinoic acid (RA) synthesis result in DiGeorge/velocardiofacial syndrome (DGS/VCFS)-like phenotypes in mouse models, including defects in septation of the outflow tract of the heart and anomalies of pharyngeal arch-derived structures including arteries of the head and neck, laryngeal-tracheal cartilage, and thymus/parathyroid. Wild-type levels of T-box transcription factor (Tbx)1 and RA signaling are required for normal pharyngeal arch artery development. Recent studies have shown that reduction of RA or loss of Tbx1 alters the contribution of second heart field (SHF) progenitor cells to the elongating heart tube. Objective: Here we tested whether Tbx1 and the RA signaling pathway interact during the deployment of the SHF and formation of the mature aortic arch.
C ardiovascular development is a complex and ordered process that is regulated by both genetic and epigenetic factors, including dynamic remodeling of the pharyngeal arch arteries (PAAs) and cardiac function. 1 Failure of blood flow during heart development and remodeling leads to cardiovascular malformations, including interruption of the aortic arch, double aortic arches, and coarctation of the aorta. 2 Despite the significant prevalence of congenital cardiovascular diseases little is known about molecules that control the subsequent remodeling into a functional vasculature. Cardiovascular defects are a major feature of the DiGeorge/velocardiofacial syndrome (DGS/VCFS), the most common genetic deletion syndrome in humans, with an incidence of 1 in 4000 live births. 3 Most DGS/VCFS patients share a 3-Mb deletion at 22q11.2, whereas 8% harbor a smaller 1.5-Mb deletion in the centromeric half of the 3-Mb region. 3 Extensive genetic analysis in human and mouse indicates that the T-box family gene, TBX1, is the major gene responsible for DGS/VCFS defects (reviewed elsewhere 4 ). Homozygous Tbx1 mutant mice have craniofacial and cardiovascular defects associated with pharyngeal hypoplasia. 4 These mice fail to form PAAs 3 to 6 and die at term with a single ventricular outlet. In addition, Tbx1 is required for normal addition of outflow tract (OFT) progenitor cells of the second heart field (SHF) to the developing heart. [5] [6] [7] Tbx1 heterozygous mutant mice display a high frequency of absence or hypoplasia of the 4th PAA at embryonic day (E)10.5 and associated great artery anomalies at later stages of development, including interrupted aortic arch, aberrant right subclavian artery and high aortic arch, components of DGS/VCFS in man. Intriguingly, the incidence of PAA associated anomalies decreases between E10.5 and fetal stages suggesting the intervention of compensatory mechanisms leading to partial phenotypic recovery. 8 Such mechanisms, likely modifying the plasticity of PAA devel-opment, remain unidentified, although several major signaling pathways that affect development and morphogenesis of PAA derivatives have been shown to interact with Tbx1, including fibroblast growth factor (FGF), 5, 9, 10 hedgehog, 11 vascular endothelial growth factor, 12 and retinoic acid (RA) 13, 14 pathways.
RA, the active derivative of vitamin A, by activating its nuclear receptors, critically regulates a variety of steps and stages of cardiovascular and pharyngeal development. 15 Knockout mice deficient for retinaldehyde dehydrogenase (Raldh)2, which catalyzes the second oxidative step in RA biosynthesis, have been used to examine RA-dependent PAA development (reviewed in 15 ). Raldh2 Ϫ/Ϫ mutants exhibit a severe deficiency in RA production and defects in early heart morphogenesis, 16 whereas RA-supplemented Raldh2 Ϫ/Ϫ embryos display OFT defects and impaired development of posterior (3rd to 6th) PAAs. 17 Moreover, disruption of RA levels can result in embryonic defects similar to those seen in DGS/VCFS. [17] [18] [19] Raldh2 Ϫ/Ϫ mutants display a posterior expansion of Fgf8 and Isl1 positive cardiac progenitors into lateral plate mesoderm; subsequently, the addition of SHF cells to the heart tube is highly compromised, especially in the OFT region. 20, 21 Recent studies suggest a potential genetic interaction between Tbx1 and RA signaling. Local increases of RA in the pharyngeal region downregulate Tbx1 expression, 14 whereas expanded Raldh2 expression and ectopic RA signaling is observed in embryos lacking Tbx1. 13, [22] [23] [24] In this study, we have investigated the possibility that reduction of RA synthesis modulates development of the 4th PAA in Tbx1 ϩ/Ϫ embryos, a feature of DGS/VCFS. During this analysis we found that reduced levels of RA associated with Raldh2 heterozygosity accelerate recovery from arterial growth delay in Tbx1 ϩ/Ϫ embryos. Unlike the situation in homozygous mutant Raldh2 and Tbx1 embryos, the cardiac contribution of the SHF is unaffected in compound heterozygous mutant embryos. Accelerated phenotypic recovery coincides with the initiation of arch artery vascular smooth muscle (VSM) differentiation. Hence, VSM differentiation is sensitive to the RA levels in Tbx1 ϩ/Ϫ embryos and is associated with more severe neural crest cell (NCC) migration defects in Tbx1 ϩ/Ϫ than Raldh2 ϩ/Ϫ ; Tbx1 ϩ/Ϫ embryos. RA deficiency therefore induces earlier recovery of DiGeorge-related aortic arch defects, suggesting that differences in levels of embryonic RA may contribute to the phenotypic variability observed in DGS/VCFS patients.
Methods

Mouse Mutants
Mice carrying null alleles at Raldh2 and Tbx1 have been previously described. 16, 25 Genotyping details are provided in the Online Data Supplement at http://circres.ahajournals.org.
Ink Injection In Situ Hybridization and Immunohistochemistry
For India ink injection, embryos were collected at E10.5 or E11.5 and injected intracardially using drawn Pasteur pipettes. Details of procedures are provided in the Online Data Supplement.
Quantitative RT-PCR
Details of procedures and primer sequences are provided in the Online Data Supplement.
Embryonic Explant Cultures
Detail of explant cultures are provided in the Online Data Supplement.
Results
Local Antagonism Between RA Signaling and Tbx1 Expression
RA generated by Raldh2 establishes the posterior border of the SHF in lateral mesoderm. 20 One major SHF regulatory gene is the T-box transcription factor, Tbx1. [5] [6] [7] To investigate the effect of RA deficiency we examined the distribution of Tbx1 in Raldh2 Ϫ/Ϫ embryos at E8.5. In wild-type (WT) embryos, Tbx1 transcripts accumulate in pharyngeal ectoderm, endoderm and cranial and splanchnic mesoderm including the SHF ( Figure  1A ). In Raldh2 ϩ/Ϫ and Raldh2 Ϫ/Ϫ mutants, this expression is progressively expanded in a caudal direction ( Figure 1B and 1C). 20 Real-time quantitative PCR confirmed that Tbx1 transcript levels are increased in Raldh2 heterozygous embryos (Ϸ1.5-fold; Online Figure I ). To evaluate whether modulation of Tbx1 expression is a direct consequence of RA signaling alteration, we investigated the effect of RA deprivation on development of the pharyngeal region in cultured explants by inhibiting RA synthesis with disulfiram, an inhibitor of the RALDH2 enzyme. 26 Treatment of pharyngeal mesoderm explants isolated from 6-to 8-somite (6s to 8s) stage embryos with disulfiram caused an increase of Tbx1 transcripts (Online Figure  II) . In contrast, trans-RA-treated explants show a reduction of Tbx1 (Online Figure II) , consistent with the observations of Roberts et al, (2005) in avian embryos. 14 These results suggest that the level of RA can modify Tbx1 expression in the pharyngeal region. However, RA impacts differently on Tbx1 expression in different pharyngeal cell types (insets in Figure 1A through 1C). Indeed, Tbx1 expression is expanded in the 13, [22] [23] [24] We analyzed the expression pattern of Raldh2, in WT and Tbx1 mutant embryos before and during the formation of the pharyngeal region at E8.5 and E9.5. In splanchnic mesoderm of WT embryos at the 7s stage, Raldh2 is expressed in the caudal part of the SHF ( Figure 1D ). In contrast, Raldh2 expression was progressively expanded cranially in Tbx1 ϩ/Ϫ and Tbx1 Ϫ/Ϫ embryos ( Figure 1E and 1F), and this expansion was maintained in the splanchnic mesoderm at the 17 to 20s stage consistent with previous reports ( Figure 1G through 1I). Because there was no detectable morphological difference between WT and Tbx1 Ϫ/Ϫ embryos at E8.5 (compare Figure 1D and 1F) these results are consistent with a direct regulation of Raldh2 by Tbx1. 22, 23 Recent data have also shown that disruption of Tbx1 function affects expression of Cyp26a1, encoding the major RAdegrading enzyme in the pharyngeal region at E9.5. 13, [22] [23] [24] At the 15s stage, we confirm that expression of Cyp26a1 was notably reduced in the pharyngeal region of Tbx1 Ϫ/Ϫ embryos versus comparable WT embryos ( Figure 1J through 1L).
Pharyngeal Segmentation in Raldh2 and Tbx1 Mutants
Abnormalities of the pharyngeal derivatives constitute the major defects of DGS/VCFS patients. To evaluate the pharyngeal morphology of Raldh2 ϩ/Ϫ , Tbx1 ϩ/Ϫ , and Raldh2 ϩ/Ϫ ;Tbx1 ϩ/Ϫ mutants, we crossed Raldh2 ϩ/Ϫ ;Tbx1 ϩ/Ϫ with WT C57Bl/6 mice (see Online supplements) and performed a histological and gene expression pattern analysis at E9.5 and E10.5. Fgf8 is required for pharyngeal development, 27 and its expression in the pharyngeal region is reduced in Tbx1 Ϫ/Ϫ mutant embryos. 28 At E9.5, Fgf8 is expressed in the lateral pharyngeal ectoderm and endoderm. Experiments of in situ hybridization and quantitative RT-PCR for Fgf8 revealed no differences between WT, single and compound Raldh2 ϩ/Ϫ ;Tbx1 ϩ/Ϫ embryos (Figure 2A through 2D; Online Figure III ). Normal levels of Raldh2 and Tbx1 are crucial for the development of the 4th pharyngeal pouch. 17, 28 Pax1 expression revealed three distinct pharyngeal pouches in compound heterozygous embryos at E10.5 ( Figure  2E through 2H). However, sectional analysis showed that the 4th pouch was unilaterally absent in 37.5% Tbx1 ϩ/Ϫ embryos (nϭ8), whereas all Raldh2 ϩ/Ϫ ;Tbx1 ϩ/Ϫ (nϭ5) had four distinct pharyngeal pouches at E10.5 (Online Figure IV ), suggesting that these two genes interact genetically to play critical, dosedependent roles during pouch formation.
The development of NCCs infiltrating the 3rd, 4th and 6th pharyngeal arches, as well as the forming OFT, is crucially involved in cardiovascular patterning and is disrupted in Tbx1 homozygous and heterozygous mutants. 29, 30 Analysis of Crabp1 expression at E9.5, which marks migrating NCCs, revealed migration defects in 100% of Tbx1 ϩ/Ϫ and 66.6% of Raldh2 ϩ/Ϫ ;Tbx1 ϩ/Ϫ embryos. Whereas two streams of NCCs were observed in WT and Raldh2 ϩ/Ϫ embryos ( Figure 2I and 2J), these streams were abnormally fused in all Tbx1 ϩ/Ϫ (nϭ5) and in 4 of 6 Raldh2 ϩ/Ϫ ;Tbx1 ϩ/Ϫ embryos ( Figure 2K and 2L; Online Figure V ). Furthermore, the NCC migration defect was more severe in Tbx1 ϩ/Ϫ than Raldh2 ϩ/Ϫ ;Tbx1 ϩ/Ϫ embryos, consistent with a genetic interaction between Tbx1 and Raldh2 during pharyngeal development. This incorrect migration has been shown to misguide these cells from their intended destination, consistent with a role for Tbx1 in NCC development. 8,29 -31 Although our analysis of the number of activating protein (AP)-2␣-positive cells revealed no significant difference in Tbx1 ϩ/Ϫ compared to Raldh2 ϩ/Ϫ ;Tbx1 ϩ/Ϫ embryos, we cannot exclude a subtle difference in the number of NCCs around the 4th PAA between these mutant embryos (Online Figure V) . 
SHF Development and OFT Morphology in Raldh2 and Tbx1 Mutants
A subset of the SHF (pharyngeal mesoderm cells) has been shown to be important for the development of the cardiac OFT. 32 Both Tbx1 and Raldh2 are required for correct deployment of the SHF. 5, 6, 20 We therefore asked whether single or compound heterozygous mutant embryos had OFT defects by analyzing the expression profile of the Fgf10-enhancer (Mlc1v-nlacZ-24) transgene expressing ␤-galactosidase in the anterior part of the SHF and OFT myocardium in single and compound heterozygote embryos. 32 Whereas dramatic caudal expansion of the SHF was observed in the absence of RA signal (Online Figure VI) , 20 we found no disruption of Mlc1v-nlacZ-24 expression in Raldh2 ϩ/Ϫ embryos at E9.5 (data not shown) and E10.5 stages (Online Figure VII) . In contrast to Tbx1 Ϫ/Ϫ embryos that exhibit reduction of Mlc1v-nlacZ-24 transgene expression in the lateral region of the dorsal pericardial wall and future pharyngeal arch region (Online Figure VI E10.5, a stage when the 6th PAAs form and the 3rd regresses. The most frequent Tbx1 ϩ/Ϫ anomalies at this stage are unilateral or bilateral loss or hypoplasia of the 4th PAAs. 8 Intracardiac injection of India ink revealed normal morphology of WT 4th PAAs at E10.5 ( Figure 3A ; Table 1 ). Although the majority of Raldh2 ϩ/Ϫ embryos displayed normal 4th PAA morphology ( Figure 3B ), 8% of Raldh2 ϩ/Ϫ embryos (nϭ25) had hypoplasia of the 4th PAAs (Table 1) . Significantly higher numbers of 4th PAA anomalies were observed in Tbx1 ϩ/Ϫ embryos (Table 1) , as previously reported. 8, 33 Defects in 4th PAA development were similar in Tbx1 ϩ/Ϫ and Raldh2 ϩ/Ϫ ;Tbx1 ϩ/Ϫ embryos at E10.5 ( Figure 3C through 3F; Table 1 ), indicating no major difference in early pharyngeal artery development when RA levels are reduced in Tbx1 ϩ/Ϫ embryos.
Analysis of aortic arch artery patterning in heterozygous Df1/ϩ mice, a model of del22q11.2 syndrome, has shown that Ϸ70% of defective arteries at E10.5 recover and develop normally. 8 To establish if the formation of the 4th PAA is delayed in compound heterozygous as it is in Tbx1 ϩ/Ϫ embryos, we performed intracardiac India ink injection at E11.5. Although a similar proportion of defects was observed in Tbx1 ϩ/Ϫ and Raldh2 ϩ/Ϫ ;Tbx1 ϩ/Ϫ embryos at E10.5, a reduced penetrance of 4th PAA defects occurred when RA levels are decreased in Tbx1 heterozygous mutants at E11.5 (57% of Tbx1 ϩ/Ϫ versus 29% of Raldh2 ϩ/Ϫ ;Tbx1 ϩ/Ϫ embryos [ Table 2 , 2 ϭ30.47; PϽ0.01]). This lower penetrance is not a survival effect, because an equal ratio of Tbx1 ϩ/Ϫ :Raldh2 ϩ/Ϫ ;Tbx1 ϩ/Ϫ embryos are observed at all time points analyzed between E8.5 and E14.5 (Online Table I ).
An absence of VSM is observed in the malformed and growth impaired 4th PAAs of Tbx1 ϩ/Ϫ embryos. 8 Potentially, the growth-restoring differences attributable to combined Raldh2 ϩ/Ϫ ;Tbx1 ϩ/Ϫ haploinsufficiency (versus single Tbx1 mutation) occurring from E10.5 and E11.5 correlates with normalization of VSM differentiation, indicated by ␣-smooth muscle actin (␣SMA) expression ( Figure 4A through 4H) . At E10.5, embryos with 4th PAA monolateral defects were sectioned and stained with anti-␣SMA. Histological analysis revealed that all reduced-size 4th PAAs of Tbx1 ϩ/Ϫ (nϭ6) and Raldh2 ϩ/Ϫ ;Tbx1 ϩ/Ϫ (nϭ8) were devoid or deficient of VSM respectively ( Figure 4C and 4D) , again indicating no striking difference in 4th PAA VSM differentiation between Tbx1 ϩ/Ϫ and Raldh2 ϩ/Ϫ ;Tbx1 ϩ/Ϫ embryos at E10.5. In contrast, at E11.5, 83.3% of Tbx1 ϩ/Ϫ embryos (nϭ6) had no or few ␣SMA-positive cells in the 4th PAAs ( Figure 4G ), whereas 66.6% of Raldh2 ϩ/Ϫ ;Tbx1 ϩ/Ϫ embryos (nϭ9) had normal ␣SMA expression ( Figure 4H ). The other embryos had 4th PAAs with a thin layer containing few ␣SMApositive cells. These data indicate that recovery from arterial growth delay in Raldh2 ϩ/Ϫ ;Tbx1 ϩ/Ϫ embryos is associated with improved differentiation of VSM.
We next examined whether vascular growth factor signaling associated with endothelial differentiation and PAA remodeling might change in Tbx1 ϩ/Ϫ and Raldh2 ϩ/Ϫ ; Tbx1 ϩ/Ϫ embryos. 2 Among these molecules we have analyzed platelet-derived growth factor (PDGF) receptor A and vascular endothelial growth factor receptor (VEGFR)2 as markers of PAA endothelial cells. 34 Immunohistochemistry with VEGFR2 revealed no difference in hypoplastic 4th PAA in Tbx1 ϩ/Ϫ and Raldh2 ϩ/Ϫ ;Tbx1 ϩ/Ϫ embryos at E11.5 (Figure 4K and 4L) . Similar results were found with PDGF receptor A (data not shown), suggesting that vascular endothelial growth factor (VEGF) and PDGF signaling are not n indicates number of scored embryos. Sm/Sm indicates both 4th PAAs are thin but patent to ink; Sm/N-P, one artery is thin, the other is not patent to ink; N-P/N-P, both arteries are not patent to ink. *One left PAA absent, 2 right PAA absent, 1 left and 2 right PAA hypoplastic. †One left PAA absent, 4 right PAA absent, 1 left and 2 right PAA hypoplastic. ‡One left PAA hypoplastic with 1 right PAA absent. §Two left PAA hypoplastic with 2 right PAA absent and 1 left PAA absent with 1 right hypoplastic. Great Artery Patterning in Tbx1 ؉/؊ and Raldh2 ؉/؊ ;Tbx1 ؉/؊ Mutants Because reduction of RA levels in Raldh2 ϩ/Ϫ ;Tbx1 ϩ/Ϫ mutants increases the number of embryos that overcome the primary defect of the 4th PAAs, we examined aortic arch artery patterning of single and compound heterozygous mutant embryos at E14.5 and E18.5 to establish whether this effect is maintained ( Figure 5 ; Table 3 ). All WT fetuses analyzed (nϭ43) had normal aortic arch morphology ( Figure 5A ). Similarly to earlier stages, one Raldh2 ϩ/Ϫ embryo (3%) exhibited a high aortic arch phenotype ( Figure 5B ; Table 3 ). This defect likely reflects Table 3 for details. Ao indicates aorta; BCA, brachiocephalic artery; CA, carotid artery; e, esophagus; Lt, left; Pt, pulmonary trunk; Rt, right; SCA, subclavian artery; t, trachea. genetic background-dependent effects. Moreover 75% of Tbx1 ϩ/Ϫ fetuses (Online Figure VIII ; Table 3 ) had normal aortic arch anatomy, which confirms a significant decrease in phenotypic penetrance compared to E11.5 embryos. Although we observe that Tbx1 haploinsufficient embryos display a spectrum of phenotypes similar to previous reports ( Figure 5C and 5D ; Table 3 ), the high aortic arch defect observed in C57BL/6 genetic background was comparatively more frequent than in the other genetic backgrounds ( Table 3) . 33 However, when compound heterozygote fetuses were examined at later stages by gross dissection (Figure 5E and 5F; Table 3 ), the penetrance of aortic arch defects was different from those observed at E11.5 and reduced but not significantly less than that of Tbx1 ϩ/Ϫ embryos (Online Figure VIII) . This indicated that primary normalization of the 4th PAA phenotype observed at E11.5 in Raldh2 ϩ/Ϫ ;Tbx1 ϩ/Ϫ embryos was not further improved during later arch artery development in contrast to the case of Tbx1 ϩ/Ϫ embryos. Together, these results suggest that reduction of RA levels (attributable to Raldh2 ϩ/Ϫ mutation) accelerates the recovery from arterial growth delay observed in Tbx1 ϩ/Ϫ embryos (Online Figure VIII) . We therefore conclude that the difference in penetrance of aortic arch defects at E11.5 suggests a role of regulated RA synthesis in determining the pathogenesis of DGS/ VCFS phenotypes associated with heterozygous loss of Tbx1.
Table 2. Fourth PAA Defects in E11.5 Embryos Scored by Ink Injection
Discussion
DiGeorge/velocardiofacial/del22q11.2 syndrome (DGS/VCFS) is characterized genetically by heterozygous deletions within chromosome 22q11 and clinically by cardiovascular defects, thymic, parathyroid and craniofacial anomalies. An important aspect of the human syndrome is phenotypic variability, which contrasts with remarkable homogeneity of the genetic defect, 3 suggesting the presence of genetic modifiers. Hence important genetic interactions exist between Tbx1 and selective genes which give DGS/VCFSlike phenotype in mice. 35 In this study we demonstrate that Tbx1 and Raldh2, encoding the enzyme responsible for synthesizing the majority of embryonic RA, interact genetically to regulate the formation of structures affected in human patients with DGS/VCFS, and that reduction of RA levels accelerates recovery from arterial growth delay observed in a del22q11 mouse models. 8 Independent studies of Tbx1 mutants demonstrate disruption in expression of RA metabolism genes including Raldh2 in the pharyngeal mesoderm of Tbx1 Ϫ/Ϫ embryos after E9.5, but it remains unclear whether this mis-regulation is direct or secondarily attributable to morphological alterations. 13, 22, 23 We observed cranial expansion of Raldh2 within the lateral mesoderm at E8.0 in Tbx1 Ϫ/Ϫ embryos (Figure 1 ). At this stage, the caudal pharyngeal region has not yet developed and no morphological differences between WT and Tbx1 Ϫ/Ϫ embryos are apparent, suggesting that Tbx1 may directly regulate Raldh2 expression levels in the pharyngeal region. 22, 23 Furthermore, increased Tbx1 expression in the P19CL6 mouse carcinoma cell line induces downregulation of Raldh2. 36 Liao et al 23 reported the identification of a T-box consensus binding site proximal to the first exon of Raldh2, reinforcing the hypothesis that Raldh2 is a direct Tbx1 target. In addition, both Tbx1 and RA regulate the expression of Cyp26 genes, responsible for inactivation of RA. 13, 24, 37 These findings raise the possibility of multifaceted regulation of local RA levels, including its synthesis and its metabolism. Regulation of the expression of Cyp26 enzymes involves multiple inputs including RA, 15 suggesting a negative feedback mechanism triggered by aberrant RA signaling in Tbx1 mutant embryos. Ectopic expression of Tbx1 in Raldh2 mutant mice is similar to alterations in Tbx1 levels in vitamin A-deficient quail embryos. 14 Our results suggest that the relationship between Tbx1 transcriptional activity and RA signaling may be cell-type specific, as Tbx1 is downregulated in the pharyngeal ectoderm and endoderm of Raldh2 mutant embryos, but is expanded caudally in lateral mesoderm. Indeed, Tbx1 dosage manipulations have revealed that different tissues have different sensitivity to Tbx1 levels. 38, 39 The variable penetrance of the 4th PAA phenotype in the del22q11 mouse model is associated with impaired VSM differentiation. 8 Our results suggest that reduction of RA levels affects the timing of growth recovery of the 4th PAAs in compound Raldh2 ϩ/Ϫ ;Tbx1 ϩ/Ϫ embryos by increasing VSM differentiation. Although the vascular system is not considered a traditional target of RA signaling, VSM cells are sensitive to its action. 40 Studies from Hirschi and colleagues have shown that RA is crucial for vascular development and for endothelial cell maturation. 41, 42 In addition, studies using all-trans RA have shown that RA can affect the proliferation, migration and differentiation of smooth muscle cells in vitro. 43 More recently, a study using Cyp26a1 Ϫ/Ϫ embryonic stem cells with high intracellular RA levels, revealed decreased differentiation, as assessed by smooth muscle cell gene expression. 44 We propose that RA affects a local signaling pathway between pharyngeal endoderm and mesenchyme in the 4th PAA. Examination of the pathways involved in remodeling of PAAs revealed that transforming growth factor (TGF)-␤ signaling enhances expression of VSM cell-specific proteins that are essential for PAA wall structure. 45 Regulation of TGF-␤ signaling by RA has been extensively reported in different cell types, indicating complex crosstalk between signals that regulate growth and differentiation. 15 Thus, it is possible that RA reduction promotes differentiation of VSM of the 4th PAA through upregulation of TGF-␤ signaling pathways. Indeed, TGF-␤ expression has been shown to be negatively and indirectly regulated by RA signaling in other contexts. 46, 47 An alternative hypothesis is that modulation of NCC migration during PAA development in compound heterozygous compared to single Tbx1 ϩ/Ϫ embryos is sufficient to modulate the penetrance of the 4th PAA defects that we observed. Several studies have revealed a role for Tbx1 in NCC differentiation into VSM as a possible explanation of the phenotype observed in Tbx1 ϩ/Ϫ mutants. 8, 30, 31 We and others 30 have provided evidence that migrating streams of NCCs are disorganized in Tbx1 ϩ/Ϫ mutant embryos. This defect has been shown to result in a reduced number of these cells reaching the 4th PAA and is associated with abnormal differentiation of arterial endothelial cells. 30 We hypothesize that reduction of RA levels may affect the haploinsufficiency of Tbx1 ϩ/Ϫ mice by increasing the number of NCCs reaching the 4th PAA and accelerating subsequent VSM differentiation.
The majority of patients with DGS/VCFS features (Ϸ80%) have a similar chromosomal 22q11.2 deletion (del22q11) 48 of 3 Mb encompassing TBX1 and other genes, but with considerable phenotypic variability. It has been shown that neither the size of the deletion nor the parental origin of the deleted chromosome influences the phenotype. 49 Although TBX1 has been shown to be the major gene underlying DGS/VCFS, genetic studies suggest that other loci may contribute to the variability of the cardiac phenotype. 49, 50 To date, only one modifier of the cardiovascular phenotype, VEGF, has been identified in del22q11 patients. 12 Our data, which demonstrate that reduced penetrance of cardiovascular defects in Tbx1 ϩ/Ϫ mice in midgestation is sensitive to RA deficiency, support the hypothesis that aberrant levels of embryonic RA could be another such modifier and that genes involved in RA synthesis, metabolism and signaling should be considered candidate modifiers of the DGS/VCFS phenotype associated with 22q11deletion.
The common clinical features associated with DiGeorge/velocardiofacial syndrome (DGS/VCFS) are congenital cardiovascular malformations, thymic and parathyroid aplasia or hypoplasia and craniofacial defects. However, despite the majority of patients diagnosed with DGS/VCFS having the same region of 22q11.2 deleted, there is wide phenotypic variation. The causes of this phenotypic variability remain unknown. Genetic studies have identified the transcription factor encoding gene Tbx1 as a major candidate gene for DGS/VCFS. TBX1 heterozygous mutant mice display absence or hypoplasia of the 4th pharyngeal arch artery (PAA) at E10.5 and associated great artery anomalies at later stages of development. Retinoic acid (RA) interacts with Tbx1, because Tbx1 expression was increased in Raldh2-deficient (Raldh2 Ϫ/Ϫ ) embryos and reduction of RA synthesis modulates development of the 4th PAA in Tbx1 ϩ/Ϫ embryos by accelerating the recovery from arterial growth delay. RA deficiency therefore induces earlier recovery of DiGeorge-related aortic arch defects, supporting the hypothesis that differences in levels of embryonic RA may contribute to the phenotypic variability observed in DGS/VCFS patients. Genes involved in RA synthesis, metabolism and signaling should be considered candidate modifiers of the DGS/VCFS phenotype associated with 22q11deletion.
